Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.55 |
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8287623 | 0.88 | HTR4 (0.70) | HRH3HTR4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL13036115 | 0.87 | HTR4 (0.52) | HRH3HTR4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL8287642 | 0.82 | DRD4 (0.67) | HTR4 | |
| SCHEMBL8286386 | 0.81 | HRH3 (0.49) | HRH3HTR4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL13479856 | 0.80 | HRH3 (0.48) | HRH3HTR4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL7960244 | 0.80 | DRD2 (0.62) | HRH3HTR4CNR1TNF | |
| SCHEMBL8287634 | 0.78 | DRD4 (0.67) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL2114876 | 0.78 | CDC25B (0.52) | HRH3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL13498624 | 0.78 | CDC25B (0.52) | HRH3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL7247107 | 0.75 | KCNH2 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834010-B2 | Modulators of peripheral 5-HT receptors | SERODUS AS (NO) | 2010-11-16 | — | — | US | disclosed |
| US-7834010-B2 | Modulators of peripheral 5-HT receptors | SERODUS AS (NO) | 2010-11-16 | — | — | US | disclosed |
| US-20090029979-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2009-01-29 | — | — | US | disclosed |
| US-20090029979-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2009-01-29 | — | — | US | disclosed |
| US-20070254874-A1 | Modulators of Preripheral 5-Ht Receptors | BIO-MEDISINSK INNOVASJON (NO) | 2007-11-01 | — | — | US | disclosed |
| US-20070254874-A1 | Modulators of Preripheral 5-Ht Receptors | BIO-MEDISINSK INNOVASJON (NO) | 2007-11-01 | — | — | US | disclosed |
| WO-2005061483-A2 | MODULATORS OF PERIPHERAL 5-HT RECEPTORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029979-A1 | 5-HTX MODULATORS | HTR7, HTR5A, HTR2C | HRH3 364/4885HTR4 9/4885CNR1 72/4885 |
| US-20070254874-A1 | Modulators of Preripheral 5-Ht Receptors | HTR4, HTR5A, HTR6 | HRH3 80/4885HTR4 1/4885CNR1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.